Literature DB >> 3989604

Relative reactivity of DTPA, immunoreactive antibody-DTPA conjugates, and nonimmunoreactive antibody-DTPA conjugates toward indium-111.

C H Paik, J J Hong, M A Ebbert, S C Heald, R C Reba, W C Eckelman.   

Abstract

Anti-human serum albumin antibody (Ab) was reacted with cyclic DTPA dianhydride (cDTPAA) at various cDTPAA/Ab molar ratios between 1 and 40. Using a carrier In titration method for DTPA and DTPA-antibody conjugate (Ab-DTPA), we determined that the above reactions produced between 0.1 and 11 DTPA molecules per either immunoreactive antibody (sAb) or nonimmunoreactive antibody (nAb). The percentage of sAb remaining after the above reactions was between 88 and 62%. The reaction of no-carrier-added 111In with the reaction mixture from cDTPAA/Ab molar ratios of 1 to 40 gave radiochemical yields less than or equal to 25% for the respective Ab-DTPA. The rest of the 111In activity was associated with free DTPA. Our results indicate that Ab-DTPA containing greater than 1 DTPA molecule per Ab is more reactive than that containing less than 1 DTPA but is about as reactive as free DTPA. This allows us to label in the presence of free DTPA and consequently prevent colloid formation. The percentage of 111In activity incorporated into sAb-DTPA from the reactions at these molar ratios was similar to that found from the uv analysis. This indicates that the reactivity of sAb-DTPA and nAB-DTPA from the same conjugation reaction is similar. As a result, we were able to conjugate about one DTPA molecule to the Ab without causing deactivation of the Ab and label it with 111In in the presence of excess DTPA. We obtained a specific activity of 6 muCi 111In per microgram of Ab using research grade 111In without further purification.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3989604

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  5 in total

1.  Effect of isoelectric point on biodistribution and inflammation: imaging with indium-111-labelled IgG.

Authors:  C I ten Kate; A J Fischman; R H Rubin; A J Fucello; D Riexinger; R A Wilkinson; L Du; B A Khaw; H W Strauss
Journal:  Eur J Nucl Med       Date:  1990

2.  Radiolabelling of monoclonal antibodies: optimization of conjugation of DTPA to F(ab')2-fragments and a novel measurement of the degree of conjugation using Eu(III)-labelling.

Authors:  M Hartikka; P Vihko; M Södervall; L Hakalahti; P Torniainen; R Vihko
Journal:  Eur J Nucl Med       Date:  1989

3.  Labeling of monoclonal antibodies with a 67Ga-phenolic aminocarboxylic acid chelate. Part I. Chemistry and labeling technique.

Authors:  J Schuhmacher; R Matys; H Hauser; W Maier-Borst; S Matzku
Journal:  Eur J Nucl Med       Date:  1986

4.  Immunosuppression by immunoglobulin deaggregation is not effective in reducing the anti-xenogeneic immunoglobulin response: experimental and clinical studies.

Authors:  G B Sivolapenko; M Kanariou; R J Edwards; A A Epenetos; M A Ritter
Journal:  Br J Cancer       Date:  1989-10       Impact factor: 7.640

5.  Comparative biodistributions of indium-111-labelled macrocycle chimeric B72.3 antibody conjugates in tumour-bearing mice.

Authors:  A Turner; D J King; A P Farnsworth; S K Rhind; R B Pedley; J Boden; R Boden; T A Millican; K Millar; B Boyce
Journal:  Br J Cancer       Date:  1994-07       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.